Natera Inc. (NTRA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, NTRA scores 70 out of 100, grade B-, with the verdict label "Roarable Buy — Sound Institutional Accumulation." The five pillars are:

• Fundamental Cash Engine, 13 / 20: The rating cites ROIC of -4.9% and an FCF yield of 0.17%. For an investor, this pillar signals that the business is not yet earning returns above its cost of capital, and that cash generation relative to the market value is thin.
• Whale 13F Flow, 19 / 20: Scored on institutional accumulation and options positioning. This is the strongest pillar and suggests large holders have been adding exposure, though the source does not itemize which holders or positions.
• Insider Conviction, 10 / 20: Scored on SEC Form 4 and Congressional PTR cluster flow. The moderate score indicates insider signaling is present but not decisive.
• Macro Regime Fit, 12 / 20: Reflects beta of 1.09 and sector sensitivity. For a prospective investor, this implies the stock tends to move somewhat more than the broader market, amplifying both upside and drawdown risk in shifting macro conditions.
• Forensic Balance Sheet, 16 / 20: Cited metrics are Altman Z of 26, Piotroski F of 7 out of 9, and Debt/Equity of 0.17. This is the second-strongest pillar and points to a balance sheet with limited leverage and solid forensic quality, even though operations remain loss-making.

Taken together, the rating frames NTRA as a company with a sound balance sheet and strong institutional support, offset by negative operating economics and a high trailing valuation relative to current earnings. Upside drivers are the institutional accumulation and balance sheet strength; the principal valuation tradeoff is that the stock trades at a $436 price against negative trailing EPS of -1.44, with forward P/E of 18 the only earnings-based multiple in the source.

Per the SEC financials, revenue grew from $1082.6M in FY 2023 to $2306.1M in FY 2025, while operating and net losses persisted in every period shown. Per the market data, operating margin is -13.4%, net margin is -9%, and gross margin is 0%. ROIC is -4.9%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 7 out of 9, with Debt/Equity of 0.17. Reported debt declined from $8088.4M in FY 2023 to $308.7M in FY 2025, and FCF turned positive in FY 2024 and FY 2025.

Per the recent news feed, the following headlines were reported for NTRA:

• A Yahoo Finance report, flagged YELLOW, framing the stock as possibly below fair value following FDA breakthrough news.
• A TradingKey report, flagged YELLOW, covering a single-day decline in market action.
• An Investing.com report, flagged YELLOW, addressing why the stock was sliding.
• A Seeking Alpha report, flagged YELLOW, describing the stock as priced for perfection amid rising competitive threats.
• A TradingView report, flagged GREEN as a CATALYST, noting a 12-month price target raised to $387.52 with implied 3% downside.
• A StockInvest.us forecast piece, flagged YELLOW.

Risk watch items named in the headlines are competitive threats and valuation. The positive catalyst cited is the FDA breakthrough news, referenced in the Yahoo Finance headline. The Butterfly Supply-Chain Graph reports no supply chain links and no proprietary signals.

• What specific products and revenue sources drive the $2306.1M FY 2025 revenue, and how are they split across customers?
• What is the source of the FDA breakthrough news referenced in the catalysts, and what is its expected commercial timeline?
• Why are trailing P/E and EV/EBITDA absent, and what would they show given the negative trailing EPS?
• Who are the institutional holders contributing to the whale 13F flow score, and how large are their positions?
• What drives the competitive threats cited in the Seeking Alpha headline, and which competitors are named?